Compare CTSO & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSO | PLUR |
|---|---|---|
| Founded | 1997 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9M | 25.5M |
| IPO Year | 2008 | 2001 |
| Metric | CTSO | PLUR |
|---|---|---|
| Price | $0.39 | $1.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.38 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 58.7K | 21.4K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.79 | 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,503,908.00 | $1,336,000.00 |
| Revenue This Year | $10.34 | $97.38 |
| Revenue Next Year | $22.41 | $293.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 48.53 | ★ 309.82 |
| 52 Week Low | $0.35 | $1.45 |
| 52 Week High | $1.19 | $5.68 |
| Indicator | CTSO | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 46.14 |
| Support Level | $0.36 | $1.56 |
| Resistance Level | $0.40 | $1.86 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 80.00 | 66.01 |
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.